This opinion paper calls attention to the potential compound effects of DBM and long COVID-19 in APOE4 carriers to substantially increase the risk for stroke, particularly in adverse and poor settings, where the mitigation of the problem is hampered by difficult access to urgent and specialized healthcare. Here, APOE is linked to Stroke.